Novocure highly likely will get FDA approval on NSCLC this year as 4 cancer drugs approved by FDA with phase 3 trials having less than 200 patients enrolled since 2019
Year
NVCR is clearly over sold A LOT as 4 cancer drugs were approved by FDA with phase 3 trials having less than 200 patients enrolled since 2019 and Novocure's Lunar phase 3 trials have total 552 patients including 133 for TTF-ICIs cohort with unprecedented astonishing result on NSCLC.
Drug
Indication
Number of Patients in Phase 3 Trial
2019
Rubraca (rucaparib)
Maintenance treatment for ovarian cancer
166
2020
Koselugo (selumetinib)
Treatment of advanced or metastatic melanoma with BRAF V600E or V600K mutation
192
2021
Dostarlimab (Jemperli)
Treatment of mismatch repair deficient (dMMR) endometrial cancer
117
2022
Vitrakvi (larotrectinib)
Treatment of solid tumors with NTRK gene fusions
175
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
